Los Angeles-based BodySphere Inc. said it has been cleared to distribute its new two-minute COVID-19 testing kit
The U.S. Food and Drug Administration has issued Emergency Use Authorization for the company’s test which uses antibodies in blood to test for current or past infection.
BodySphere said its tests have a 91 percent clinical specificity rate and a 99 percent clinical sensitivity rate.
Results are delivered on site in as fast as two minutes, rather than current COVID-19 tests, which take two to seven days for results. In addition, the test can be administered as easily as a glucose test but is designed strictly for use by medical professionals, the company said.